Brolucizumab Brand Name– BEOVU

What is Brolucizumab

Brolucizumab is a human vascular endothelial growth factor (VEGF) inhibitor approved for the treatment of neovascular (wet) age-related macular degeneration (AMD).

The drug is administered via intravitreal injection and must be given under aseptic conditions by a qualified physician.

The initial 3 doses are administered monthly (approximately every 25 to 31 days), after which the dosing interval may be extended to every 8 to 12 weeks.

Brolucizumab is contraindicated for use in patients with ocular or periocular infections and patients with active intraocular inflammation. Instruct patients to immediately report if ocular pain, redness of the eye, photophobia, or blurred vision occurs as these may be signs of a detached retina or of an eye infection.


  • macular degeneration

For the treatment of neovascular (wet) age-related macular degeneration (AMD)

Side Effects

  1. antibody formation
  2. blurred vision
  3. cataracts
  4. conjunctival hyperemia
  5. conjunctivitis
  6. corneal erosion
  7. endophthalmitis
  8. erythema
  9. foreign body sensation
  10. iritis
  11. keratitis
  12. lacrimation
  13. myocardial infarction
  14. ocular hemorrhage
  15. ocular hypertension
  16. ocular infection
  17. ocular inflammation
  18. ocular pain
  19. pruritus
  20. rash
  21. retinal detachment
  22. retinal hemorrhage
  23. stroke
  24. thromboembolism
  25. urticaria
  26. uveitis
  27. visual impairment

Monitoring Parameters

  • intraocular pressure


  • breast-feeding
  • children
  • contraception requirements
  • driving or operating machinery
  • increased intraocular pressure
  • infants
  • infertility
  • neonates
  • ocular infection
  • ocular inflammation
  • pregnancy
  • reproductive risk
  • retinal detachment
  • thromboembolic disease


There are no drug interactions associated with Brolucizumab products.